BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 4608340)

  • 21. [The Parkinson syndrome].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2111. PubMed ID: 4773983
    [No Abstract]   [Full Text] [Related]  

  • 22. [Current treatment of the Parkinsonian syndrome].
    Voiculescu V
    Neurol Psihiatr Neurochir; 1973; 18(6):519-23. PubMed ID: 4790485
    [No Abstract]   [Full Text] [Related]  

  • 23. Statokinesimetric analysis of the postural control in parkinsonism.
    Gregoric M; Lavric A
    Agressologie; 1977; 18 Spec No():45-8. PubMed ID: 900360
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effects of L-dopa and stereotaxic surgery in Parkinsonism].
    Sugita K; Mutsuga N; Takaoka Y; Takeda A
    No To Shinkei; 1970 Sep; 22(9):1103-8. PubMed ID: 4918927
    [No Abstract]   [Full Text] [Related]  

  • 25. CSF biopterin levels and clinical features of patients with juvenile parkinsonism.
    Furukawa Y; Nishi K; Kondo T; Mizuno Y; Narabayashi H
    Adv Neurol; 1993; 60():562-7. PubMed ID: 8420192
    [No Abstract]   [Full Text] [Related]  

  • 26. Psychiatric changes in patients treated with levodopa. I. The clinical experiment.
    Knopp W
    Neurology; 1970 Dec; 20(12):23-30. PubMed ID: 4924341
    [No Abstract]   [Full Text] [Related]  

  • 27. Stabilographic findings in central vestibular disturbances.
    Cernacek J; Jagr J; Harman B; Vyskocil S
    Agressologie; 1973; 14(Spec No D):21-6. PubMed ID: 4547508
    [No Abstract]   [Full Text] [Related]  

  • 28. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.
    Yahr MD; Duvoisin RC; Hoehn MM; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1968; 93():56-63. PubMed ID: 4885744
    [No Abstract]   [Full Text] [Related]  

  • 29. The Eaton Collaborative Study of levodopa therapy in parkinsonism: a summary.
    Keenan RE
    Neurology; 1970 Dec; 20(12):46-59. PubMed ID: 5531294
    [No Abstract]   [Full Text] [Related]  

  • 30. L-dopa and amantadine in the therapy of parkinsonism.
    Weeth JB; Shealy CN; Mercier DA
    Wis Med J; 1969 Nov; 68(11):325-8. PubMed ID: 4901055
    [No Abstract]   [Full Text] [Related]  

  • 31. L-DOPA therapy in drug-induced parkinsonism evaluated by the method measuring the facial expression.
    Kimura N; Tsukue I
    Hiroshima J Med Sci; 1971 Mar; 20(1):55-63. PubMed ID: 5121129
    [No Abstract]   [Full Text] [Related]  

  • 32. [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].
    Danielczyk W; Korten JJ
    Med Monatsschr; 1971 Oct; 25(10):472-9. PubMed ID: 5122447
    [No Abstract]   [Full Text] [Related]  

  • 33. [Utility of L-dopa in the treatment of Parkinson's disease and parkinsonism-like diseases].
    Herskovits E; Matera R; Gacitua EF
    Medicina (B Aires); 1972; 32(1):10-4. PubMed ID: 5019629
    [No Abstract]   [Full Text] [Related]  

  • 34. Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson's disease.
    Bloem BR; Beckley DJ; van Dijk JG; Zwinderman AH; Remler MP; Roos RA
    Mov Disord; 1996 Sep; 11(5):509-21. PubMed ID: 8866492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical use of levodopa in the treatment of Parkinson's disease.
    McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD
    Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056
    [No Abstract]   [Full Text] [Related]  

  • 36. [Current treatment of Parkinsonism with amantadine hydrochloride].
    Gerstenbrand F; Gründig E; Musiol A
    Pol Tyg Lek; 1972 Jul; 27(23):878-9. PubMed ID: 5040531
    [No Abstract]   [Full Text] [Related]  

  • 37. Postural reflexes in patients on long-term neuroleptic medication.
    Beckley DJ; Bloem BR; Singh J; Remler MP; Wolfe NS; Roos RA
    Clin Neurol Neurosurg; 1991; 93(2):119-22. PubMed ID: 1678998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 39. Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis.
    Nygaard TG
    Adv Neurol; 1993; 60():577-85. PubMed ID: 8420194
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.